Pulse Medical Imaging Technology (Shanghai) Co. Ltd. has raised more than $100 million in a series C funding round to accelerate the R&D, clinical trials and commercialization of its products. “Pulse plans to use the funds to accelerate the commercialization of its fractional flow reserve (FFR) estimating systems,” Xiaojie Lin, marketing director of Pulse, told BioWorld. FFR is a method to measure blood pressure and flow within a coronary artery to check on the possibility that the stenosis impedes oxygen delivery to the heart muscle.
Contrary to the broader markets, BioWorld’s Cancer Index is down by 22% this year, losing more than 7% throughout the month of July, despite oncology driving several high-money deals and accounting for 38%, the lion’s share, of financings. Both the Nasdaq Biotech Index and the Dow Jones Industrial Average are tracking similarly for the year, and are up by 13.2% and 15.2%, respectively, as of Aug. 10.
Gentibio Inc. has raised $157 million to develop its engineered regulatory T cells (Tregs), setting itself a target to cure type 1 diabetes and treat other diseases caused by the immune system. Boston-based Gentibio launched in August last year with $20 million seed funding from Orbimed, Novartis Venture Fund and RA Capital. Those investors stayed on into the next round, which was led by Matrix Capital Management with participation by Avidity Partners and JDRF T1D Fund.
Hong Kong Exchanges and Clearing Ltd. (HKEX) has taken the first step towards allowing listings on the market via special purpose acquisition companies (SPACs), also known as “blank check” companies. The move has left biotech companies wondering if the change could provide the next big opportunity to join the market after pre-revenue companies were first allowed to list there under a 2018 main board listing rule paved the path for them to do so.
Cell therapy company Zhuhai Grit Biotechnology Inc. completed a series A+ financing of undisclosed value to advance its lead tumor-infiltrating lymphocyte (TIL) program, GT-101 for advanced solid tumors, into the clinic by year end while also developing other TIL candidates in its pipeline.
While the 441 med-tech financings completed so far this year are nearly as much as this point last year (446), the amount of money raised, at $33.43 billion, is 17% below the amount raised through early August of 2020 ($40.14 billion). Just two months ago, the volume of financings was 10% higher than last year, indicating a recent slowdown in activity. Nevertheless, 2021 appears to be on track to beat the $40.7 billion raised in 2019, and it is already ahead of the full year amounts for 2017 and 2018.